Recent Customer Citations Using FLICA® Caspase-1 Assay Kits

Recently, our customers have published two research articles using our FLICA® Kits to detect caspase-1 activity.

The first article, authored by researchers at the Utrecht University Department of Infectious Diseases and Immunology, studied the pathogen that causes foodborne disease.

Recent Customer Publication Using FLICA Assays

Researchers at Harvard Medical School and  Schepens Eye Research Institute recently published a study using several of our FLICA apoptosis assays to detect caspase activity in retinal pigment epithelial cells.

Kim LA., Amarnani D, Gnanaguru G, Tsen WA, Vavvas DG, and D'Amore PA. (2014.) Tamoxifen Toxicity in Cultured Retinal Pigment Epithelial Cells Is Mediated by Concurrent Regulated Cell Death Mechanisms. Invest. Ophthalmol. Vis. Sci., 55(8), 4747-4758. [Abstract]

"Caspase activity was evaluated by caspase-1, -3, -8, and -9 specific inhibition... Caspase activity was verified with the fluorochrome-labeled inhibitor of caspases (FLICA) probe specific for each caspase."

ICT Owners Complete ALS Ice Bucket Challenge

Lee and Hed douse themselves in ice water to bring awareness to ALS and medical research, challenge industry colleagues

August 27, 2014 - BLOOMINGTON, Minn. -- Challenge accepted! Dr. Brian Lee and Ms. Sally Hed, co-owners of ImmunoChemistry Technologies, were nominated to complete the ALS Ice Bucket Challenge. They accepted the challenge on this sunny day in August and made a donation to the ALS Association.

Screening Imidazolium-based Compounds for Cancer-Fighting Effects

Congratulations to our customers at the Frederick National Laboratory for Cancer Research and the Universidad Metropolitana School of Environmental Affairs for publishing their recent study of the effects of imidazolium-based compounds on 60 human cancer cell lines in the September 2014 issue of MedChemComm.

To assess potential toxicity of the compounds, they measured apoptosis via caspase activation using our FLICA® (Fluorescent Labeled Inhibitors of Caspases) probes that bind covalently with active caspase effector enzymes.

Animal-Free Recombinant Proteins Now Available

ICT has introduced over 200 animal-free recombinant proteins for use as ELISA standards and in other research and development applications.

• Produced in yeast
• Naturally endotoxin-free
• Convenient 5 microgram size

• Species:
  

  Bovine	Catfish	Dolphin	Feline	Human	Ovine	Swine
  Canine	Chicken	Equine	Guinea Pig	Mouse	Rabbit	Turkey

• Available proteins:
  
  

  APRIL	CCL5	IFN beta	IL-2	IL-13	IL-22	TNFSF15
  CCL11	CXCL9	IFN gamma	IL-4	IL-15	IL-23A	VEGF-A
  CCL2	CXCL10	IGF-1	IL-5	IL-16	IL-24
  CCL20	CXCL11	IGF-2	IL-6	IL-17A	MIF
  CCL3	GM-CSF	IL-1 alpha	IL-8	IL-17F	SCF
  CCL3L1	IFN alpha	IL-1 beta	IL-10	IL-18	TNF alpha
  CCL4	IFN alpha 1	IL-1F5	IL-12 p40	IL-21	TNFSF13

See all Recombinant Proteins


The immunology-related recombinant proteins are natural complements to ICT's suite of ELISA Solutions™ protein-stabilizing reagents for immunoassay development. ICT offers a large portfolio of tools to improve and enhance an ELISA, including Blocking Buffers, Wash Buffers, Plate Coating Buffers, Conjugate Stabilizers, Sample Diluents, Substrates, Stop Solutions, ELISA Plates and Accessories, and ELISA/assay development services. View the complete portfolio at http://www.immunochemistry.com/products/elisa-solutions.html.

Contact us with any questions: 1-800-829-3194; sales{at} immunochemistry.com.

Bright Minds, Bright Solutions. ImmunoChemistry Technologies’ mission is to advance scientific discovery by developing innovative products for apoptosis detection, cellular analysis, and immunoassay development.

ICT Introduces Two New HRP Conjugate Stabilizer Formulations

Conjugate stabilizers prolong the shelf-life of conjugated antibodies and other proteins, enhancing their utility in ELISA and Western applications.

HRP (horseradish peroxidase) Conjugate Stabilizer formulations are used to dilute, store, and reconstitute HRP-conjugated antibodies while preserving native protein configuration and activity. This stabilization maintains the signal-generating capabilities of HRP-conjugated antibodies during storage, inhibits nonspecific binding, and minimizes background signal. The two newest HRP conjugate stabilizers join ICT's other protein-stabilizing reagents in the range of ELISA Solutions™ to optimize assay development.

UCSF Scientists Develop Cell Reprogramming Technique to Generate Hepatocytes for Therapeutic Use

Regenerative Medicine Research News:

The liver possesses some capacity to regenerate or heal itself after injury. When the liver is damaged beyond this capacity, a whole-liver transplant is the preferred treatment of many medical professionals, but the demand for donor livers far exceeds supply. Thus, scientists are developing regenerative medicine therapies to treat damaged livers.

Human hepatocytes have been generated in vitro from induced pluripotent stem cells (iPSC), but these cells do not adequately proliferate and function after transplantation into mouse models of liver damage for therapeutic success.

In a study published in Nature Feb 23, 2014, UCSF scientists describe how they developed an induced multipotent progenitor cell (iMPC) reprogramming technique to differentiate